CRISPR Therapeutics AG (CRSP)
100.96
+0.12 +0.12%
NASDAQ
May 13, 16:59
USD
View All Key Stats
Key Stats
| Income Statement | |
| Revenue (TTM) | 1.101M |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | -5.65 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | -392.30M |
| Profitability | |
| Gross Profit Margin (Quarterly) | -- |
| Profit Margin (Quarterly) | -20.99K% |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield | 0% |
| Price and Valuation | |
| Market Cap | 7.650B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio | 6370.53 |
| PE Ratio | -- |
| Price to Book Value | 4.237 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Free Cash Flow (Quarterly) | -107.69M |
| Return on Equity | Upgrade |
View All CRSP News
News
-
WireHeadlineTime (ET)
-
SA Breaking News05/13 15:09
-
MT Newswires05/12 12:29
-
Globe Newswire05/12 11:00
-
Yahoo05/12 06:14
-
Yahoo05/11 12:12
-
Yahoo05/11 06:40
-
Yahoo05/07 11:38
-
Yahoo05/07 06:40
-
MT Newswires05/07 06:02
-
Globe Newswire05/06 16:01
-
SA Breaking News05/04 13:57
-
Yahoo05/04 06:00
-
Yahoo05/01 06:10
-
Yahoo04/29 22:01
-
Yahoo04/29 16:17
-
Globe Newswire04/29 08:30
-
Yahoo04/29 03:26
-
Globe Newswire04/28 16:01
-
Yahoo04/28 12:18
-
Yahoo04/28 09:56
View All Events
Events
| Date | Type | Description |
|---|---|---|
| 07/27/2021 00:00 | Earnings Results | Q2 2021 Earnings Results |
| 04/27/2021 00:00 | Earnings Results | Q1 2021 Earnings Results |
| 02/16/2021 00:00 | Earnings Results | Q4 2020 Earnings Results |
| 10/28/2020 00:00 | Earnings Results | Q3 2020 Earnings Results |
| 07/27/2020 00:00 | Earnings Results | Q2 2020 Earnings Results |
| 06/11/2020 14:00 EDT | AGM | 2019 Annual General Meeting |
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- Description: CRISPR Therapeutics AG is a gene-editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 is a technology that allows for precise, directed changes to genomic DNA. The company advanced programs target beta-thalassemia and sickle cell disease, two hemoglobinopathies that have a high unmet medical need.
- URL: http://www.crisprtx.com
- Investor Relations URL: http://ir.crisprtx.com/
- HQ State/Province: N/A
- Sector: Healthcare
- Industry: Biotechnology
- Equity Style: Mid Cap/Blend
- Next Earnings Release: Jul. 27, 2021
- Last Earnings Release: Apr. 27, 2021
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 100.96 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Top Fund Holders
| Symbol | Name | Weighting |
|---|---|---|
| GNOM | Global X Genomics & Biotechnology ETF | 3.95% |
| NEXTX | Shelton Green Alpha | 3.56% |
| MID326 | Global Healthcare Div F | 3.45% |
| IMPLX | ERShares US Large Cap Fund™ Inst | 3.18% |
| IDNA | iShares Genomics Immnlgy & Hlthcr ETF | 2.96% |
| EARK.NO | Emerge ARK Global Disruptive Innovt ETF | 2.82% |
| ADNRX | American Beacon ARK Transfmt Innov R6 | 2.63% |
| ARKK | ARK Innovation ETF | 2.47% |
| ARKG | ARK Genomic Revolution ETF | 2.35% |
| BBH | VanEck Vectors Biotech ETF | 2.02% |
| IMPAX | ERShares US Small Cap Fund™ Inst | 1.75% |
| RYCFX | Rydex Biotechnology C | 1.62% |
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- CRSP Tweets Stocktwits
Advertisement
